Close Menu

NEW YORK – Natera said on Wednesday that it has received the CE mark for its Signatera personalized circulating tumor DNA test.

The test is optimized for molecular residual disease (MRD) assessment and for monitoring treatment in cancer patients.

With the CE mark in hand, Natera can now make the test available to clinics and hospital systems throughout Europe.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.